A recent study generated a radiomics signature based on dynamic contrast-enhanced MRI to distinguish between low (recurrence score < 18) and non-low (recurrence score > 18) Oncotype DX risk groups in estrogen receptor (ER)–positive invasive breast cancer [40]. This evidence concerns the gene ESR1 and invasive breast carcinoma.